...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Pharmacology and Pharmacotherapeutics >Metabolic syndrome in schizophrenia: Differences between antipsychotic-na?ve and treated patients
【24h】

Metabolic syndrome in schizophrenia: Differences between antipsychotic-na?ve and treated patients

机译：精神分裂症的代谢综合征：未接受过抗精神病药的患者与接受治疗的患者之间的差异

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Metabolic syndrome (MetS) has been recognized as a risk factor for cardiovascular morbidity and mortality in general population and in patients with severe mental illnesses like schizophrenia. This paper reviews studies on MetS in schizophrenia and related psychotic disorders, and assesses the contribution of antipsychotics toward the development of MetS. Databases of Medline (PubMed), PsycINFO, and Scopus were searched for MetS, psychotic disorders, and antipsychotic drugs from inception till present. Prevalence of MetS in patients with schizophrenia was found to be ranging from 3.3% to 68.0%. Prevalence in antipsychotic-na?ve and antipsychotic-treated patients ranged between 3.3-26.0% and 32.0-68.0% respectively, and was higher in younger patients, female gender and Hispanics, and lower in African-Americans and Orientals. Prevalence of metabolic abnormalities was higher in patients receiving second generation antipsychotics (SGAs), especially with clozapine, olanzapine, and risperidone, as compared to first generation antipsychotics (FGAs). Antipsychotic-induced changes on metabolic indices became evident after 2 weeks and reached maximum at 3 months of treatment. There is a need to sensitize the mental health professionals at all levels about the need of screening and monitoring for MetS in patients receiving antipsychotics.Keywords: Antipsychotic, metabolic syndrome, schizophrenia
机译：代谢综合症（MetS）被认为是普通人群和精神分裂症等严重精神疾病患者心血管疾病发病率和死亡率的危险因素。本文综述了精神分裂症和相关精神病性疾病中MetS的研究，并评估了抗精神病药对MetS的发展的贡献。从开始到现在，一直在Medline（PubMed），PsycINFO和Scopus的数据库中搜索MetS，精神病和抗精神病药物。发现精神分裂症患者的MetS患病率为3.3％至68.0％。初次接受抗精神病药物治疗的患者和接受抗精神病药物治疗的患者的患病率分别为3.3-26.0％和32.0-68.0％，在年轻患者，女性和西班牙裔患者中较高，而在非裔美国人和东方人中较低。与第一代抗精神病药（FGA）相比，接受第二代抗精神病药（SGA），尤其是氯氮平，奥氮平和利培酮的患者代谢异常的患病率更高。抗精神病药引起的代谢指标变化在2周后变得很明显，在治疗3个月时达到最大。有必要使各级精神卫生专业人员对接受抗精神病药的患者进行MetS筛查和监测的认识提高认识。关键词：抗精神病药，代谢综合征，精神分裂症

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号